Platelet-active drugs : the relationships among dose, effectiveness, and side effects.
Patrono
C
C
Department of Medicine and Aging, Università degli Studi G D'Annunzio, Chieti, Italy. Cpatrono@unich.it
Coller
B
B
Dalen
J E
JE
FitzGerald
G A
GA
Fuster
V
V
Gent
M
M
Hirsh
J
J
Roth
G
G
D001241:Aspirin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011225:Pre-Eclampsia / Q000517:prevention & control; D011247:Pregnancy; D013927:Thrombosis / Q000517:prevention & control*
D016861:Cyclooxygenase Inhibitors; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D004176:Dipyridamole; D001241:Aspirin